Kerri Fitzgerald

DocwireNews

The U.S. Food and Drug Administration approved Keytruda&reg; (pembrolizumab) for firstline treatment of patients with metastatic or unresectable recurrent <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/is-there-any-association-between-green-tea-consumption-and-the-risk-of-head-and-neck-squamous-cell-carcinoma-finding-from-a-case-control-study/">head and neck squamous cell carcinoma</a> (HNSCC).The decision was based on results from the randomized, multicenter, three-arm, open-label, active-controlled KEYNOTE-048 that included 882&nbsp;patients with <a href="https://www.docwirenews.com/abstracts/effect-pregabalin-radiotherapy-neuropathic/">metastatic HNSCC</a> who had not previously received systemic therapy for metastatic disease or with recurrent disease who were considered incurable by local therapies.Patients were randomized 1:1:1 to receive pembrolizumab as a single agent, pembrolizumab plus chemotherapy (carboplatin or cisplatin and fluorouracil), or cetuximab plus chemotherapy (carboplatin or cisplatin and fluorouracil). Patients were stratified by tumor PD-L1 expression, HPV status, and Eastern Cooperative Oncology Group performance status score.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Reminder that <a href="https://twitter.com/hashtag/lenvatinib?src=hash&amp;ref_src=twsrc%5Etfw">#lenvatinib</a> + <a href="https://twitter.com/hashtag/pembrolizumab?src=hash&amp;ref_src=twsrc%5Etfw">#pembrolizumab</a> is FDA approved for MSS <a href="https://twitter.com/hashtag/endometrialcancer?src=hash&amp;ref_src=twsrc%5Etfw">#endometrialcancer</a>. &#129310;&#127996;the open phase 3 trial will confirm phase2 results. Coming to a future ascocancer meeting&hellip; <a href="https://twitter.com/hashtag/asco19?src=hash&amp;ref_src=twsrc%5Etfw">#asco19</a> <a href="https://twitter.com/hashtag/gyncsm?src=hash&amp;ref_src=twsrc%5Etfw">#gyncsm</a> <a href="https://t.co/6BgS2e1N1C">https://t.co/6BgS2e1N1C</a>
&mdash; Deanna Teoh, M.D., M.S., FACOG (@DeannaTeoh) <a href="https://twitter.com/DeannaTeoh/status/1135624325233430528?ref_src=twsrc%5Etfw">June 3, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><h2>Significantly improved overall survival with pembrolizumab</h2>Patients receiving pembrolizumab plus chemotherapy had statistically significant improvement in overall survival (OS) compared with those receiving cetuximab plus chemotherapy: The median OS was 13.0 months and 10.7 months, respectively (hazard ratio [HR] = 0.77; 95% CI, 0.63-0.93; P=0.0067). The results were similar among a cohort of patients with a Combined Positive Score (CPS) &ge;20 (HR=0.69; 95% CI, 0.51-0.94) and those with a CPS &ge;1 (HR=0.71; 95% CI, 0.57-0.88).The study also resulted in statistically significant improvements in OS for the subgroups of patients with PD&#8209;L1 CPS&nbsp;&ge;1 HNSCC and PD-L1 CPS &ge;20 HNSCC who were randomized to receive pembrolizumab as a single agent compared with cetuximab plus chemotherapy. In the CPS &ge;1 subgroup, the median OS was 12.3 months for the pembrolizumab arm and 10.3 months for the cetuximab plus chemotherapy arm (HR=0.78; 95% CI, 0.64-0.96; P=0.0171). For the CPS &ge;20 subgroup, the median OS was 14.9 months for the pembrolizumab arm and 10.7 months for the cetuximab plus chemotherapy arm (HR=0.61; 95% CI, 0.45-0.83; P=0.0015). At the time of the interim analysis, there was no significant difference in OS between the pembrolizumab as a single agent arm and the cetuximab plus chemotherapy arm for the overall population.There were no significant differences in progression-free survival among the different treatment cohorts.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma <a href="https://t.co/rye3hXl1Nq">https://t.co/rye3hXl1Nq</a> Great news are coming! Next step? Biomkers &ndash; the right patient to Immuno vs the one to go to EXTREME!
&mdash; FRoitberg_MD (@FroitbergM) <a href="https://twitter.com/FroitbergM/status/1138423118345703424?ref_src=twsrc%5Etfw">June 11, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The most common adverse events (AEs) reported in patients receiving pembrolizumab as a single agent were fatigue, constipation, and rash. The most common AEs reported in patients who received pembrolizumab in combination with chemotherapy were nausea, fatigue, constipation, vomiting, mucosal inflammation, diarrhea, decreased appetite, stomatitis, and cough.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

FDA Approves Keytruda® for Firstline Head and Neck Cancer

Head and Neck Cancer

The FDA approved Keytruda® (pembrolizumab) for firstline treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe